Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris
By
- AMS
posted
Jan 12, 2021 11:14 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience
- AMS
Added Jul 09, 2020
Blog Entry
The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy
- AMS
Added Dec 23, 2020
Blog Entry
Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus
- AMS
Added Jun 08, 2021
Blog Entry
Challenges faced by patients with morphea in the era of SARS-CoV-2
- AMS
Added Jun 09, 2020
Blog Entry
Rituximab monotherapy in mild pemphigus
- AMS
Added Oct 26, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic